Immune Therapeutics, Inc. (OTCMKTS:IMUN) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain OfficersItem 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Immune Therapeutics, Inc. (the “Company”) has appointed Mr. Rudy Williams to serve as its Chief Operations Officer. There was no prior arrangement between Mr. Williams and any Company representative prior to his appointment.
Rudy Williams is the former president of International Engineering Services, Inc. (IESINC); one of the country’s largest minority owned engineering service company in the early and late seventies, 1969-1985. He sold IES in 1985. In the mid-eighties, Mr. Williams identified the need for a government affairs firm dedicated to small business issues and formed The Phoenix Group. The Phoenix Group is a public affairs company that specializes in federal government, legislative representation, and internal relations. Mr. Williams also created Direct Pharmacy Service, Inc. (DPSI) in the early nineties with his partner James Hill (now deceased). DPSI became the largest Mail Order Pharmacy, operating from their facilities in the Southern sector of the U.S. The interface with government regulations, rules extended to DPSI to become a Pharmacy Benefit Management Company which intensified relations with federal government health care regulations. Mr. Williams has a BS/MS degree in Electrical Engineering; attended Tuskegee Institute, Arizona State University and Massachusetts Institute of Technology (MIT).
Item 8.01 Other Events
On August 24, 2017, the Company issued a press release announcing that its majority owned subsidiary, Cytocom, Inc., has appointed Dr. John Abeles as its Chairman, Director and CEO. Dr. Abeles will also serve as a Senior Advisor to the Company.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are filed herewith.
|
Exhibit No. |
Description |
|
99.1 |
Press Release |
Immune Therapeutics, Inc. ExhibitEX-99.1 2 ex99-1.htm Immune Therapeutics,…To view the full exhibit click here
About Immune Therapeutics, Inc. (OTCMKTS:IMUN)
Immune Therapeutics, Inc. is a biotechnology company. The Company is involved in the manufacturing, distribution and marketing of therapies to combat chronic, life-threatening diseases through the activation and modulation of the body’s immune system using its patented immunotherapy. The Company’s products and immunotherapy technologies are designed to improve the treatment of cancer, infections, such as human immunodeficiency virus (HIV)/acquired immuno deficiency syndrome (AIDS), chronic inflammatory diseases and autoimmune diseases. Its technology platform is built on various immunotherapies, such as Low Dose Naltrexone (LDN) and Methionine-Enkephalin (MENK). Its technology offers treatment for a range of cancers. The Company’s clinical programs involve immunotherapy with Methionine-Enkephalin (MENK) (sometimes referred to as opioid growth factor) and its Low Dose Naltrexone (LDN) product or LodonalTM, which stimulates the immune system even in patients with advanced cancer.
